Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of China Medical University, Shenyang 110001, China.
Department of Urinary Surgery, Northeast International Hospital, Shenyang 110623, China.
Ageing Res Rev. 2024 Nov;101:102528. doi: 10.1016/j.arr.2024.102528. Epub 2024 Oct 2.
Frailty is the most problematic expression of population ageing, which has been associated with increased mortality and complications among patients with gastric cancer (GC). However, previous evidence about the frailty prevalence and outcomes in frail populations with gastric cancer remains unknown.
Eligible studies were searched in Embase, PubMed, Scopus, and Web of Science to explore the prevalence and impact of frailty in patients with gastric cancer from inception until November 25, 2023. The pooled prevalence of frailty, hazard ratio (HR), and odds ratio (OR) corresponding 95 % confidence intervals (CI) in mortality and postoperative complications estimates were analyzed.
A total of 24 studies containing 75,357 GC patients were involved. The prevalence of frailty in gastric cancer was 27 % (95 % CI = 24-30; I = 96.7 %; p = 0.000). Frailty was independently associated with an increased hazard ratio for mortality (adjusted HR = 2.14; 95 % CI = 1.60-2.86; I = 67.3 %, p = 0.000). Furthermore, frailty was significantly associated with an increased odds ratio for postoperative complication in GC patients (adjusted OR = 2.65; 95 % CI = 2.17-3.25; I = 0.0 %, Cochran's Q = 1.20, p = 0.878).
The prevalence of frailty in gastric cancer is common and has a significant adverse effect on GC patients' outcomes. Our findings highlight the importance of routine frailty assessment in GC patients, which may provide prognostic outcomes.
衰弱是人口老龄化最突出的表现,与胃癌(GC)患者的死亡率和并发症增加有关。然而,关于患有胃癌的衰弱人群的衰弱患病率和结局的先前证据尚不清楚。
在 Embase、PubMed、Scopus 和 Web of Science 中搜索合格的研究,以探讨 2023 年 11 月 25 日之前患有胃癌患者衰弱的患病率和影响。分析了衰弱的总患病率、死亡率和术后并发症发生率的风险比(HR)和优势比(OR)及其 95%置信区间(CI)。
共纳入 24 项研究,包含 75357 例 GC 患者。胃癌衰弱的患病率为 27%(95%CI=24-30;I=96.7%;p=0.000)。衰弱与死亡率的调整后 HR 升高独立相关(调整后 HR=2.14;95%CI=1.60-2.86;I=67.3%;p=0.000)。此外,衰弱与 GC 患者术后并发症的调整后 OR 升高显著相关(调整后 OR=2.65;95%CI=2.17-3.25;I=0.0%,Cochran's Q=1.20,p=0.878)。
胃癌衰弱的患病率较高,对 GC 患者的结局有显著的不良影响。我们的研究结果强调了对 GC 患者进行常规衰弱评估的重要性,这可能提供预后结果。